Aktiesnakken — September 2013
-
Eneste negative var den lave pris for fabrikken, men det er trods alt udenfor Jans kontrol
-
ja den fabrik. sikke
noget svindel. -
ja det er stadig joker
-
Er det ikke det her: http://clinicaltrials.gov/ct2/show/NCT00496652?term=zalutumumab&rank=3
-
der står primary data outcome i midt 2012, så de er godt nok forsinket. Endelige data forventes i 2016
-
Ville Arzerra Bendamustine data blive præsenteret på CLL kongressen i september?
-
spændende. Novod nævner også at der vil komme yderligere Arzerra/Ibrutinib kombi data i 2013
-
Herudover får vi jo topline fra Idealisib/Arzerra phase III i slutningen af 2014 nok
-
ofa/ibrutinib havde primary completion i juni, samme som ofa sc i rrms.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind